Omeros

Omeros

Yahoo Finance • 16 days ago

Accelerant, Harmonic surge, Cisco slides premarket on margin outlook

Investing.com - U.S. stock index futures pointed higher on Thursday, as investors digested fresh corporate earnings and deal news while continuing to assess the outlook for inflation and interest rates. By 06:19 ET (10:19 GMT), the Dow fu... Full story

Yahoo Finance • 16 days ago

Omeros outlines Q3 2026 interest expense of about $6.5M while advancing $287,000 NTAP for YARTEMLEA

Earnings Call Insights: Omeros Corporation (OMER) Q2 2026 MANAGEMENT VIEW * "YARTEMLEA generated $32.2 million in gross sales in its first full quarter on the market," "operations generated $4.1 million of positive cash flow during the... Full story

Yahoo Finance • 18 days ago

Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?

It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core ear... Full story

Yahoo Finance • last month

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired

(RTTNews) - Today's top biotech gainers include Entera Bio, following an oversubscribed private placement financing; Gossamer, which is progressing toward a planned Seralutinib NDA submission in September; First Tracks, which has been firi... Full story

Yahoo Finance • last month

Omeros gains as AstraZeneca's Ultomiris fails in rare blood disorder

[blood cells] cosmin4000/iStock via Getty Images * The failure of a phase 3 trial of AstraZeneca's (AZN [https://seekingalpha.com/symbol/AZN]) Ultomiris (ravulizumab) phase to treat transplant-associated thrombotic microangiopathy, a ra... Full story

Yahoo Finance • last month

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER).  Such investors are advised to contact Danielle Peyton at newactio... Full story

Yahoo Finance • last month

Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return

Omeros Corp. (NASDAQ:OMER) is one of the 10 best stocks under $10 that could triple. On June 26, Omeros Corp. (NASDAQ:OMER) released an update regarding the Committee for Medicinal Products for Human Use's (CHMP) review of a marketing aut... Full story

Yahoo Finance • last month

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER).  Such investors are advised to contact Danielle Peyton at newactio... Full story

Yahoo Finance • last month

Noteworthy Tuesday Option Activity: DINO, ZS, OMER

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in HF Sinclair Corp (Symbol: DINO), where a total of 31,865 contracts have traded so far, representing approximately 3.2 million unde... Full story

Yahoo Finance • 2 months ago

Omeros Corporation Investigated by the Portnoy Law Firm

LOS ANGELES, July 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Omeros Corporation, (“Omeros" or the "Company") (NASDAQ: OMER) investors that the firm has initiated an investigation into possible securities fraud, and may fil... Full story

Yahoo Finance • 2 months ago

OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm

LOS ANGELES, July 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or “the Company”) (NASDAQ... Full story

Yahoo Finance • 2 months ago

Is Omeros Corporation (OMER) the Best Get Rich Quick Stock to Buy Right Now?

Omeros Corporation (NASDAQ:OMER) is among the best get rich quick stocks to buy right now. On June 26, Brandon Folkes from H.C. Wainwright trimmed the price target on Omeros Corporation (NASDAQ:OMER) to $33 from $40 and reaffirmed a Buy ra... Full story

Yahoo Finance • 2 months ago

Acadia rises as EU backs Rett syndrome therapy

[Diagnosis Rett syndrome and tablets on a wooden table.] designer491 Acadia Pharmaceuticals (ACAD [https://seekingalpha.com/symbol/ACAD]) added ~13% on Friday after an expert panel of the EU drug regulator, the European Medicines Agency,... Full story

Yahoo Finance • 2 months ago

NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?

Deciding between NovoCure (NASDAQ:NVCR) and Omeros (NASDAQ:OMER) requires a look at two different stages of medical innovation. Both companies aim to solve difficult health challenges using unique scientific approaches. NovoCure is establ... Full story

Yahoo Finance • 2 months ago

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

Choosing between Intellia Therapeutics (NASDAQ:NTLA) and Omeros (NASDAQ:OMER) in 2026 requires balancing the explosive potential of gene editing against the steady rollout of newly approved orphan disease treatments. Intellia Therapeutics... Full story

Yahoo Finance • 5 months ago

Omeros Corp (OMER) Q4 2025 Earnings Call Highlights: A Turnaround with Strategic Deals and FDA ...

This article first appeared on GuruFocus. Net Income (Q4 2025): $86.5 million or $1.22 per share. Net Loss (Q3 2025): $30.9 million or $0.47 per share. Net Gain from Zaltnibart Transaction: $237.6 million. Non-GAAP Adjusted Net Income (Q4... Full story

Yahoo Finance • 5 months ago

Omeros Non-GAAP EPS of $3.14 beats by $2.78

* Omeros press release [https://seekingalpha.com/pr/20458005-omeros-corporation-reports-fourth-quarter-and-year-end-2025-financial-results] (OMER [https://seekingalpha.com/symbol/OMER]): Q4 Non-GAAP EPS of $3.14 beats by $2.78. * At De... Full story

Yahoo Finance • 5 months ago

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

– Conference Call Today at 4:30 p.m. ET SEATTLE, March 31, 2026--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended Dece... Full story

Yahoo Finance • 5 months ago

After-Hours Earnings Report for March 31, 2026 : NKE, PVH, RH, NCNO, OMER, PLAY, BYND, DUOT, REKR, DGXX, BHST, SPWH

The following companies are expected to report earnings after hours on 03/31/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Nike, Inc. (NKE)is reporting for the quarter ending February 28, 2026. The sh... Full story

Yahoo Finance • 5 months ago

Earnings week ahead: NKE, TLRY, SPCE, BYND, NNDM, CAG, and more

[Nest of Eggs] LindaJoHeilman As the calendar turns from March to April, a holiday-shortened week still delivers a diverse set of earnings with the potential to offer fresh directional cues. Consumer and brand momentum will be in focus w... Full story